SLS Stock Summary and Trading Ideas (Sellas Life Sciences Group | NASDAQ:SLS)

SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

Sellas Life Sciences Group trades on the NASDAQ stock market under the symbol SLS.

As of September 1, 2026, SLS stock price declined to $13.22 with 5,474,413 million shares trading.

SLS has a beta of 0.05, meaning it tends to be less sensitive to market movements. SLS has a correlation of 0.00 to the broad based SPY ETF.

SLS has a market cap of $2.67 billion. This is considered a Mid Cap stock.

In the last 3 years, SLS traded as high as $15.88 and as low as $.50.

The top ETF exchange traded funds that SLS belongs to (by Net Assets): XBI, IWM, VTI, IWO, VXF.

SLS has outperformed the market in the last year with a price return of +588.5% while the SPY ETF gained +19.3%. SLS has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +42.0% and +1.7%, respectively, while the SPY returned +1.0% and -1.4%, respectively.

SLS support price is $12.51 and resistance is $14.18 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SLS shares will trade within this expected range on the day.